Izotropic to Present at Investor Conference February 6th

Rhea-AI Summary

Izotropic (OTCQB: IZOZF) has announced its upcoming presentation at the Small Cap Growth Virtual Investor Conference on February 6, 2025. CEO Robert Thast will present from 3:00-3:30 PM EST, discussing the company's recent achievements, regulatory approvals in the U.S. and EU, near-term objectives, and funding options.

This marks the company's first public presentation since revealing its new regulatory strategy for U.S. FDA approval and timeline for launching IzoView, their dedicated breast CT imaging system. The device features contrast-enhancement for breast cancer screening, working alongside 3D mammography for patients with dense breast tissue.

The virtual conference will include a live Q&A session, and attendance is complimentary for individual and institutional investors, advisors, and analysts. Those unable to attend can access an archived webcast of the presentation.

News Market Reaction

+22.12%

1 alert

+22.12% News Effect

On the day this news was published, IZOZF gained 22.12%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

- CEO to present overview of Company value proposition, unique catalysts, and near-term objectives -

- Event includes live Q and A, attendance is complimentary -

- Individual and institutional investors, advisors, and analysts welcome -

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 3, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce that CEO Robert Thast will be presenting at the Small Cap Growth Virtual Investor Conference this week and will be covering key aspects of the Company's recent achievements, U.S. and EU regulatory approvals, near-term-objectives, and funding options.

Date: February 6, 2025
Time: 3:00 - 3:30 pm EST / 12:00 - 12:30 pm PST
1 x 1 Meetings: See availability here: https://calendly.com/izotropic/meeting-with-ceo

This will be the first public presentation by Izotropic since unveiling its new regulatory strategy for U.S. FDA approval and timelines to market launch of its first medical imaging device, IzoView- a dedicated breast CT imaging system, with contrast-enhancement for breast cancer screening adjunctive to digital breast tomosynthesis, commonly referred to as 3D mammography, for patients with dense breast tissue.

After the formal presentation, attendees will have the opportunity and are encouraged to ask relevant questions through an interactive portal. For anyone registered who cannot attend the live event, an archived webcast will be made available.

Please pre-register at the following link:
https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/4849543/izotropic-corporation-otcqb-izozf-cse-izo

About Izotropic:

More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca.

About Virtual Investor Conferences®

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

Forward-Looking Statements:

This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.

These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.

Contacts:

Izotropic Corporation
Robert Thast
Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-800-IZOCORP ext. 3
Email: bthast@izocorp.com

General Inquiries
Telephone: 1-604-825-4778 or 1-800-IZOCORP ext. 1
Email: info@izocorp.com

Virtual Investor Conferences
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239311

FAQ

When is Izotropic (IZOZF) presenting at the Small Cap Growth Virtual Investor Conference?

Izotropic is presenting on February 6, 2025, from 3:00-3:30 PM EST / 12:00-12:30 PM PST.

What will be covered in Izotropic's (IZOZF) February 2025 investor presentation?

The presentation will cover recent achievements, U.S. and EU regulatory approvals, near-term objectives, funding options, and the company's new regulatory strategy for FDA approval.

What is Izotropic's (IZOZF) IzoView system designed for?

IzoView is a dedicated breast CT imaging system with contrast-enhancement, designed for breast cancer screening as an adjunct to 3D mammography for patients with dense breast tissue.

How can investors attend Izotropic's (IZOZF) February 2025 presentation?

Investors can attend by pre-registering through the Virtual Investor Conferences website, and those who cannot attend live can access an archived webcast.

Will there be a Q&A session during Izotropic's (IZOZF) February 2025 presentation?

Yes, attendees will have the opportunity to ask questions through an interactive portal following the formal presentation.